Move to topTop
August 28, 2012

Tokyo -- Terumo Corporation (TSE: 4543 Section 1) today announced the start of a clinical study to evaluate the performance of a newly developed product intended to prevent adhesion formation after surgical procedures. The study will take place at several medical institutions in Europe.

Post-surgical adhesions occur frequently in abdominal and pelvic surgery and are potentially dangerous as they may cause internal organs to attach to the surgical site or to other organs. Adhesions are associated with significant post-surgical morbidity including bowel obstruction, infertility, and chronic pain. An adhesion barrier is a film like material that can be used to reduce post-surgical adhesions by separating internal tissues and organs.

To prevent post-surgical adhesions and improve patient Quality of Life, Terumo has developed a spray gel adhesion barrier which is easily applied even in complex surgical fields in both laparoscopic and open surgery. While in place, the adhesion barrier acts as a physical barrier to separate traumatized tissue surfaces so that they do not adhere to one another while they heal. The Terumo product is made of a bio-absorbable polymer. Once the tissue surfaces heals, the adhesion barrier dissolves and is absorbed by the body, eliminating as such any possible consequence of permanent presence of foreign material inside the body.

Professor De Wilde, from Pius Hospital, Oldenburg, Germany, the coordinating investigator of the study said: "I am very pleased to lead this study with a new adhesion barrier because post-operative adhesions are still a major problem in our daily practice. We are now a big step forward and hope that the results will meet our expectations".

Dr. Korell, from Johanna Etienne Hospital, Neus, Germany, who enrolled the first patients in this study commented: "I am very excited with the opportunity to be the first in the world to test this product in the patient. The system is easy to use and our expectations are high that this promising new material will be efficient".

By introducing its adhesion barrier Terumo aims for safer surgical procedures, better patients outcome, and increased Quality of Life.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.